• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Consumer Cyclical·EVE.AX
Share

EVE Health Group Limited Stocks

A$ 0.02Last Updated 23.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

A$ 3.67M

A$ 0.02
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Subiaco, Australia, Eve Health Group Limited, originally incorporated in 2003 as EVE Investments Limited, is an international provider of health, wellness, and nutritional products. The company operates across Australia, New Zealand, the Asia Pacific region, and North America. Its activities include the production of organic tea tree oils, the distribution of botanical oils, and the supply of a wide array of other oils such as essential oils, hydrosols, extracts, carrier oils, and seed oils. Furthermore, Eve Health Group offers organic raw honey and raw honey probiotic concentrates, alongside contract manufacturing services. A key area of its focus is developing medical nutrition solutions for chronic and lifestyle ailments, exemplified by Gluco Smooth, a product designed to help manage type 2 diabetes by moderating post-meal blood sugar levels, as well as providing various dietary intervention programs.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds have ramped up their bets against the euro to a 2020 high

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

24.10.2026 04:37

A key Novartis drug failed to meet expectations. The stock price fell

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026